Mifamurtide switches macrophage polarization to a TAM-like intermediate M1/M2 phenotype and reduces IL-17R levels and STAT3 activation, thereby inhibiting cell growth and inducing tumor-cell differentiation [46]. Here, STAT3 is linked to neoplasm.